The ASXL-BAP1 axis: New factors in myelopoiesis, cancer and epigenetics

Leukemia

Volumn 27, Issue 1, 2013, Pages 10-15

  Abdel Wahab, O ^a   Dey, A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GENENTECH INC   (United States)

Author keywords

ASXL1; ASXL2; BAP1; chronic myelomonocytic leukemia; myelodysplastic syndrome; Polycomb

Indexed keywords

ASXL1 PROTEIN; ASXL2 PROTEIN; BAP1 PROTEIN; HISTONE H3; HOST CELL FACTOR 1; N ACETYLGLUCOSAMINE; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CELL FUNCTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CUTANEOUS MELANOMA; ENZYME ACTIVITY; ENZYME STABILITY; EPIGENETICS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HISTONE METHYLATION; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; KIDNEY CARCINOMA; LEUKEMIA CELL; LUNG CARCINOMA; MYELODYSPLASTIC SYNDROME; MYELOPOIESIS; NONHUMAN; OPITZ SYNDROME; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SOMATIC MUTATION; UVEA MELANOMA; WESTERN BLOTTING;

CELL TRANSFORMATION, NEOPLASTIC; EPIGENOMICS; HUMANS; MYELOPOIESIS; NEOPLASMS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84873568880     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.288     Document Type: Review

References (46)

1. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 2012; 337: 1541-1546.
2. Abdel-Wahab O, Adli M, Lafave LM, Gao J, Hricik T, Shih AH et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22: 180-193.
3. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009; 284: 34179-34188.
4. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138: 389-403.
5. Sinclair DA, Milne TA, Hodgson JW, Shellard J, Salinas CA, Kyba M et al. The additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes. Development 1998; 125: 1207-1216.
6. Park UH, Yoon SK, Park T, Kim EJ, Um SJ. Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}. J Biol Chem 2011; 286: 1354-1363.
7. Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010; 285: 18-29.
8. Cho YS, Kim EJ, Park UH, Sin HS, Um SJ. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 2006; 281: 17588-17598.
9. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C et al. Loss-offunction additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010; 115: 38-46.
10. Aravind L, Iyer LM. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle 2012; 11: 119-131.
11. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118: 6920-6929.
12. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25: 1200-1202.
13. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
14. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
15. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506.
16. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24: 1062-1065.
17. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
18. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010; 465: 243-247.
19. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32: 491-502.
20. Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008; 32: 503-518.
21. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998; 16: 1097-1112.
22. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008; 68: 6953-6962.
23. Kovacs G, Erlandsson R, Boldog F, Ingvarsson S, Muller-Brechlin R, Klein G et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 1988; 85: 1571-1575.
24. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-1413.
25. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011; 48: 856-859.
26. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43: 668-672.
27. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43: 1022-1025.
28. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43: 1018-1021.
29. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012; 44: 17-19.
30. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751-759.
31. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44: 53-57.
32. Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 2010; 30: 5071-5085.
33. Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de Vries P et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet 2011; 43: 729-731.
34. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
35. Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol 2009; 29: 2181-2192.
36. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 2011; 60: 3-11.
37. Capotosti F, Guernier S, Lammers F, Waridel P, Cai Y, Jin J et al. O-GlcNAc transferase catalyzes site-specific proteolysis of HCF-1. Cell 2011; 144: 376-388.
38. Knez J, Piluso D, Bilan P, Capone JP. Host cell factor-1 and E2F4 interact via multiple determinants in each protein. Mol Cell Biochem 2006; 288: 79-90.
39. Tyagi S, Chabes AL, Wysocka J, Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell 2007; 27: 107-119.
40. Hanover JA, Krause MW, Love DC. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 2012; 13: 312-321.
41. Baskind HA, Na L, Ma Q, Patel MP, Geenen DL, Wang QT. Functional conservation of Asxl2, a murine homolog for the Drosophila enhancer of trithorax and polycomb group gene Asx. PLoS One 2009; 4: e4750.
42. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
43. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118: 5227-5234.
44. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
45. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
46. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.